China’s Alphamab Oncology raises $60m in Series B financing

Photo by Louis Reed on Unsplash

Chinese biopharmaceutical company Alphamab Oncology has raised $60 million in a Series B financing round, led by Hudson Bay Capital Management LP, a US and UK-based asset management firm.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.